ICU Equipment in Ohio

Codonics, Inc. is a Cleveland-based medical technology innovator specializing in patient safety and medication management solutions. Founded in 1982, the company has deployed over 60,000 installations across more than 110 countries. The Safe Label System (SLS)—Codonics' flagship product—enhances medication safety through real-time barcode scanning and automated labeling at the point of care, reducing administration errors and ensuring TJC and ISMP compliance. SLS integrates seamlessly with anesthesia drug carts and pharmacy workflows across operating rooms, intensive care units, patient floors, and pharmacy departments. Additional offerings include the SLS-Wave (hands-free scanning), Safe Waste System (controlled substance tracking), WasteLog (waste verification), and SLS Administration Tool (formulary management). Recognized as a Top 100 Healthcare Technology Company of 2024 and awarded Medication Safety Technology Company of the Year 2025, Codonics delivers solutions that streamline clinical workflows, improve charge capture, ensure 340B compliance, and prevent medication errors in perioperative and procedural settings.

Synapse Biomedical Inc. is an FDA-approved medical device company specializing in neurostimulation products for treating chronic respiratory insufficiency. Founded in 2002 and based in Oberlin, Ohio, the company develops minimally invasive diaphragm pacing systems designed to reduce mechanical ventilator dependence in patients with spinal cord injuries, amyotrophic lateral sclerosis (ALS), and other neurological conditions. The company's flagship product, the NeuRx® Diaphragm Pacing System (DPS), electrically stimulates the diaphragm to assist ventilation and restore respiratory muscle function. With over 2,000 patients successfully treated and coverage by Medicare, Medicaid, and private insurance, Synapse continues to advance respiratory care standards. The company also offers the TransAeris® system for preventing ventilator-induced diaphragm dysfunction (VIDD) in critically ill patients requiring temporary stimulation.

N8 Medical LLC is a clinical-stage medical device company specializing in antimicrobial coating technology based on ceragenins—a novel class of active compounds that mimic innate immune system antimicrobial peptides. The company's lead product, CeraShield, is an antimicrobial coating applied to indwelling medical devices and implants to prevent hospital-acquired infections (HAIs) and biofilm formation. The flagship device is the CeraShield Endotracheal Tube (ETT), designed to prevent Ventilator-Associated Pneumonia (VAP), the most common and costly HAI in ICU settings with estimated global treatment costs exceeding $10 billion annually. The FDA has designated CeraShield ETT as a "Breakthrough Device" and it is cleared for routine clinical use in Canada, Colombia, Brazil, and the UAE, with FDA approval anticipated. N8 Medical's pipeline includes additional CeraShield-coated devices: an antimicrobial absorbable pacemaker envelope for prevention of cardiac implantable electronic device (CIED) infections, and coated pedicle screws for orthopedic implant-associated infection prevention. The company is also developing CeraShield-coated hemodialysis catheters. N8 Medical operates as part of N8 Biosciences holding company and maintains a pharmaceutical subsidiary, Kinnear Pharmaceuticals, advancing therapeutic drug development using ceragenins for cystic fibrosis and other conditions. The company has received multiple NIH SBIR grants and maintains partnerships with government agencies including USAMRIID for biodefense applications.